Optiscan Imaging (OIL.AX) Aandeel Koers
Optiscan Imaging Koers
De omzet van Optiscan Imaging is de afgelopen 19 jaar met 12,5% per jaar gedaald tot 448.769,00 AUD. De nettowinstmarge van Optiscan Imaging ligt op -1.556,7% en is ten opzichte van -417,9% enkele jaren eerder gedaald.
Optiscan Imaging aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Optiscan Imaging bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Optiscan Imaging
The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.
Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.
The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.
Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.
Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.
Optiscan Imaging Ltd is primarily present in Australia.
Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.
Omgezet tegen de huidige wisselkoers noteert het aandeel Optiscan Imaging op 0,09 EUR (0,15 AUD).
Het aandeel Optiscan Imaging (OIL.AX) is genoteerd aan 1 beurzen, waaronder: ASX (OIL.AX).
Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.
De omzet van Optiscan Imaging bedraagt 448.769,00 AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Optiscan Imaging bedraagt -6,99 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Optiscan Imaging bedraagt momenteel -22,42. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Optiscan Imaging-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Optiscan Imaging bedraagt momenteel 349,01. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Optiscan Imaging-aandeel.
De Eulerpool Kwaliteitsscore voor Optiscan Imaging is 2/10.
De ISIN van Optiscan Imaging is AU000000OIL4. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Optiscan Imaging is 932111. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Optiscan Imaging is OIL.AX. Onder dit beurstickersymbool wordt het Optiscan Imaging-aandeel op de beurs verhandeld.
Optiscan Imaging aandeel
Optiscan Imaging Peer Group
Optiscan Imaging Ticker
Optiscan Imaging FIGI
Alle fundamentals en diepgaande analyse van Optiscan Imaging
Onze aandelenanalyse van het Optiscan Imaging-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Optiscan Imaging. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: